THERAPEUTICS
Both low-dose and micro-dose 17β-oestradiol reduced hot flushes
| The first 150 words of the full text of this article appear below. |
G A Bachmann
Dr G A Bachmann, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA; gloria.bachmann@umdnj.edu
STUDY DESIGN
randomised, placebo-controlled trial.
concealed.*
blinded (patients, healthcare providers, and data collectors).*
STUDY QUESTION
48 centres in the USA.
425 healthy postmenopausal women
40 years of age (mean age 53 y, mean time since menopause 9 y) who had an average of
7 (mean 10) moderate or severe hot flushes per day for
1 week during screening. Exclusion criteria included abnormal Pap test result, abnormal vaginal bleeding, and a history of thrombophlebitis or thromboembolic disorder.
transdermal patches delivering 0.023 mg/day 17β-oestradiol (E2) plus 0.0075 mg/day levonorgestrel (low-dose group, n = 145), 0.014 mg/day E2 (micro-dose group, n = 147), or no E2 (placebo group, n = 133).
frequency and severity of hot flushes, treatment response (
75% or
90% reduction in hot flush frequency), and adverse events.
12 weeks.
84% (intention-to-treat analysis).
MAIN RESULTS
All
Vanderbilt University Medical Center, Nashville, Tennessee, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
